Chase Investment Counsel Corp Catalyst Pharmaceuticals, Inc. Transaction History
Chase Investment Counsel Corp
- $299 Million
- Q4 2024
A detailed history of Chase Investment Counsel Corp transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Chase Investment Counsel Corp holds 54,000 shares of CPRX stock, worth $1.24 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
54,000Holding current value
$1.24 Million% of portfolio
0.38%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
339Shares Held
96.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$428 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$184 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$143 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$130 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$69.1 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.35B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...